Post-earnings recap
Reported
Wed, Oct 23, 2013
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
Eli Lilly's earnings report showed a positive surprise in EPS, which contributed to a slight increase in stock price. Investors reacted favorably to the earnings beat, despite the lack of revenue data and guidance. The company's focus on innovation suggests potential for future growth, but the absence of specific guidance leaves some uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.11 | N/A | +6.02% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, indicating a focus on future product developments. They emphasized their commitment to innovation in the healthcare space.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering innovative treatments.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—